Workflow
AestheFill代理权争议迎进展 涉及两家上市公司
Zheng Quan Shi Bao Wang·2025-09-12 13:08

Group 1 - The arbitration regarding the agency rights of AestheFill in mainland China has seen a significant development, with the emergency arbitrator rejecting the request from Datou Medical to revoke the exclusive authorization of Lizhen (Xiamen) Medical Technology Co., Ltd. as the agent [1] - The emergency arbitrator confirmed that REGEN Biotech, Inc. must continue supplying AestheFill products to Datou Medical and cannot deny its status as the exclusive distributor [1] - The decision aims to balance the interests of both parties while ensuring a stable supply of AestheFill products in the Chinese market, minimizing the impact of the dispute on the end market and consumers [1] Group 2 - Despite the ongoing arbitration, the legal status of Lizhen (Xiamen) as the exclusive agent for AestheFill in mainland China remains intact, potentially weakening Datou Medical's claims of illegal deprivation of exclusive distribution rights [2] - REGEN's main reason for seeking to terminate the cooperation agreement with Datou Medical is the latter's transfer of agency business to its controlling shareholder, which violates the exclusivity agreement [2] - The product AestheFill has been renamed to "Zhenai Suofei" and continues to be supplied normally, indicating that the arbitration dispute has not materially affected sales [2] Group 3 - *ST Suwu is facing multiple delisting risks, including false reporting of revenue and profits, which could lead to mandatory delisting due to significant violations [3] - The stock price of *ST Suwu has repeatedly fallen below 1 yuan, putting it at risk of delisting due to its low market value [3] - The company is also dealing with major operational and governance risks, including unresolved large fund occupation issues by its controlling shareholder and ongoing litigation regarding exclusive agency agreements for core aesthetic products [3]